406 related articles for article (PubMed ID: 29908917)
1. Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study.
Marshall BDL; Goedel WC; King MRF; Singleton A; Durham DP; Chan PA; Townsend JP; Galvani AP
Lancet HIV; 2018 Sep; 5(9):e498-e505. PubMed ID: 29908917
[TBL] [Abstract][Full Text] [Related]
2. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
[TBL] [Abstract][Full Text] [Related]
3. MSM at Highest Risk for HIV Acquisition Express Greatest Interest and Preference for Injectable Antiretroviral PrEP Compared to Daily, Oral Medication.
Biello KB; Mimiaga MJ; Santostefano CM; Novak DS; Mayer KH
AIDS Behav; 2018 Apr; 22(4):1158-1164. PubMed ID: 29119472
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
Cambiano V; Miners A; Dunn D; McCormack S; Ong KJ; Gill ON; Nardone A; Desai M; Field N; Hart G; Delpech V; Cairns G; Rodger A; Phillips AN
Lancet Infect Dis; 2018 Jan; 18(1):85-94. PubMed ID: 29054789
[TBL] [Abstract][Full Text] [Related]
5. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
Psaros C; Goodman GR; Lee JS; Rice W; Kelley CF; Oyedele T; Coelho LE; Phanuphak N; Singh Y; Middelkoop K; Griffith S; McCauley M; Rooney J; Rinehart AR; Clark J; Go V; Sugarman J; Fields SD; Adeyeye A; Grinsztejn B; Landovitz RJ; Safren SA;
J Int AIDS Soc; 2024 May; 27(5):e26252. PubMed ID: 38783534
[TBL] [Abstract][Full Text] [Related]
6. Nondaily preexposure prophylaxis for HIV prevention.
Anderson PL; García-Lerma JG; Heneine W
Curr Opin HIV AIDS; 2016 Jan; 11(1):94-101. PubMed ID: 26633641
[TBL] [Abstract][Full Text] [Related]
7. Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China.
Meyers K; Wu Y; Qian H; Sandfort T; Huang X; Xu J; Zhang J; Xia W; Glidden D; Wu H; Shang H
AIDS Behav; 2018 Apr; 22(4):1217-1227. PubMed ID: 28707025
[TBL] [Abstract][Full Text] [Related]
8. Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.
Zhao R; Fairley CK; Cook AR; Phanuphak N; He S; Tieosapjaroen W; Chow EPF; Phillips TR; Jin Tan RK; Wei Y; Shen M; Zhuang G; Ong JJ; Zhang L
Lancet Glob Health; 2024 Feb; 12(2):e243-e256. PubMed ID: 38245115
[TBL] [Abstract][Full Text] [Related]
9. Willingness and preferences for long-acting injectable PrEP among US men who have sex with men: a discrete choice experiment.
Cole SW; Glick JL; Campoamor NB; Sanchez TH; Sarkar S; Vannappagari V; Rinehart A; Rawlings K; Sullivan PS; Bridges JFP
BMJ Open; 2024 Apr; 14(4):e083837. PubMed ID: 38653510
[TBL] [Abstract][Full Text] [Related]
10. Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral Human Immunodeficiency Virus Preexposure Prophylaxis: A Mathematical Model.
Maloney KM; Le Guillou A; Driggers RA; Sarkar S; Anderson EJ; Malik AA; Jenness SM
J Infect Dis; 2021 Jan; 223(1):72-82. PubMed ID: 32882043
[TBL] [Abstract][Full Text] [Related]
11. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
[TBL] [Abstract][Full Text] [Related]
12. Population-level effectiveness of pre-exposure prophylaxis for HIV prevention among men who have sex with men in Montréal (Canada): a modelling study of surveillance and survey data.
Doyle CM; Milwid RM; Cox J; Xia Y; Lambert G; Tremblay C; Otis J; Boily MC; Baril JG; Thomas R; Blais AD; Trottier B; Grace D; Moore DM; Mishra S; Maheu-Giroux M
J Int AIDS Soc; 2023 Dec; 26(12):e26194. PubMed ID: 38054579
[TBL] [Abstract][Full Text] [Related]
13. Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.
Parsons JT; Rendina HJ; Whitfield TH; Grov C
AIDS Behav; 2016 Jul; 20(7):1390-9. PubMed ID: 27000145
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.
Juusola JL; Brandeau ML; Owens DK; Bendavid E
Ann Intern Med; 2012 Apr; 156(8):541-50. PubMed ID: 22508731
[TBL] [Abstract][Full Text] [Related]
15. The promise and pitfalls of long-acting injectable agents for HIV prevention.
Landovitz RJ; Kofron R; McCauley M
Curr Opin HIV AIDS; 2016 Jan; 11(1):122-8. PubMed ID: 26633643
[TBL] [Abstract][Full Text] [Related]
16. Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?
John SA; Whitfield THF; Rendina HJ; Parsons JT; Grov C
AIDS Behav; 2018 Apr; 22(4):1184-1189. PubMed ID: 28913659
[TBL] [Abstract][Full Text] [Related]
17. A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.
Kovarova M; Swanson MD; Sanchez RI; Baker CE; Steve J; Spagnuolo RA; Howell BJ; Hazuda DJ; Garcia JV
J Antimicrob Chemother; 2016 Jun; 71(6):1586-96. PubMed ID: 27002074
[TBL] [Abstract][Full Text] [Related]
18. Added Benefits of Pre-Exposure Prophylaxis Use on HIV Incidence with Minimal Changes in Efficiency in the Context of High Treatment Engagement Among Men Who Have Sex with Men.
Singleton AL; Marshall BDL; Zang X; Nunn AS; Goedel WC
AIDS Patient Care STDS; 2020 Dec; 34(12):506-515. PubMed ID: 33216618
[TBL] [Abstract][Full Text] [Related]
19. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
Blair HA
Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.
Koss CA; Hosek SG; Bacchetti P; Anderson PL; Liu AY; Horng H; Benet LZ; Kuncze K; Louie A; Saberi P; Wilson CM; Gandhi M
Clin Infect Dis; 2018 Jan; 66(2):213-219. PubMed ID: 29020194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
